Suppr超能文献

大剂量肌内或口服胆钙化醇治疗维生素 D 缺乏/不足老年患者的疗效和安全性。

Efficacy and safety of high dose intramuscular or oral cholecalciferol in vitamin D deficient/insufficient elderly.

机构信息

Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Cukurova University, Adana 01330, Turkey.

出版信息

Maturitas. 2012 Aug;72(4):332-8. doi: 10.1016/j.maturitas.2012.04.011. Epub 2012 May 20.

Abstract

OBJECTIVES

To evaluate and compare the effects and safety of high dose intramuscular (IM) or oral cholecalciferol on 25-hydroxyvitamin D [25(OH)D] levels, muscle strength and physical performance in vitamin D deficient/insufficient elderly.

STUDY DESIGN

Randomized prospective study.

MAIN OUTCOME MEASURES

116 ambulatory individuals aged 65 years or older living in a nursing home were evaluated. Eligible patients with 25(OH)D levels <30 ng/ml (n=66) were randomized to IM or Oral groups according to the administration route of 600,000 IU cholecalciferol. Demographic and descriptive data were collected. Biochemical response was measured at baseline, 6th and 12th weeks. Muscle strength was measured from quadriceps by using a hand-held dynamometer and physical performance was evaluated by short physical performance battery (SPPB) at the beginning and 12th week.

RESULTS

Among the screened ambulatory elderly only 5.2% (n=6) had adequate vitamin D levels. 37.1% (n=43) were vitamin D deficient and 57.7% (n=67) were insufficient. After administration of one megadose of vitamin D, mean serum 25(OH)D levels increased significantly at 6th week (32.72±9.0 ng/ml) and at 12th week (52.34±14.2 ng/ml) compared with baseline (11.76±7.6 ng/ml) in IM group (p<0.0001). In Oral group levels were 47.57±12.7 ng/ml, 42.94±13.4 ng/ml and 14.87±6.9 ng/ml, respectively (p<0.0001). At 12th week the increase in IM group was significantly higher than Oral group (p=0.003). At the end of the study period, serum 25(OH)D levels were ≥30 ng/ml in all patients in IM group and in 83.3% of the patients in the Oral group. Quadriceps muscle strength and SPPB total score increased significantly in both groups and SPPB balance subscale score increased only in IM group. Six patients (9.6%) developed hypercalciuria, no significant adverse events were observed.

CONCLUSION

In vitamin D deficient/insufficient elderly, a single megadose of cholecalciferol increased vitamin D levels significantly and the majority of the patients reached optimal levels. Although both administration routes are effective and appear to be safe, IM application is more effective in increasing 25(OH)D levels and balance performance.

摘要

目的

评估和比较高剂量肌内(IM)或口服胆钙化醇对维生素 D 缺乏/不足的老年患者 25-羟维生素 D [25(OH)D]水平、肌肉力量和身体表现的影响和安全性。

研究设计

随机前瞻性研究。

主要观察指标

评估了 116 名居住在养老院的 65 岁或以上的活动能力个体。根据 600,000IU 胆钙化醇的给药途径,将 25(OH)D 水平<30ng/ml 的合格患者(n=66)随机分为 IM 或口服组。收集人口统计学和描述性数据。基线、第 6 周和第 12 周测量生化反应。使用手持测力计测量股四头肌的肌肉力量,第 12 周评估短体表现电池(SPPB)的身体表现。

结果

在所筛选的活动能力老年人中,仅有 5.2%(n=6)的维生素 D 水平充足。37.1%(n=43)为维生素 D 缺乏,57.7%(n=67)为不足。给予一剂大剂量维生素 D 后,IM 组第 6 周(32.72±9.0ng/ml)和第 12 周(52.34±14.2ng/ml)的血清 25(OH)D 水平较基线(11.76±7.6ng/ml)显著升高(p<0.0001)。口服组分别为 47.57±12.7ng/ml、42.94±13.4ng/ml和 14.87±6.9ng/ml(p<0.0001)。第 12 周时,IM 组的增加明显高于口服组(p=0.003)。研究期末,IM 组所有患者和口服组 83.3%的患者血清 25(OH)D 水平≥30ng/ml。两组的股四头肌力量和 SPPB 总分均显著增加,仅 IM 组的 SPPB 平衡子量表评分增加。6 名患者(9.6%)发生高钙尿症,未观察到明显的不良事件。

结论

在维生素 D 缺乏/不足的老年患者中,单次大剂量胆钙化醇可显著提高维生素 D 水平,大多数患者达到最佳水平。虽然两种给药途径均有效且似乎安全,但 IM 应用在提高 25(OH)D 水平和平衡性能方面更有效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验